Studies have confirmed that despite the expression of the Fas receptor on HNSCC cells, FasL monotherapy did not induce significant effects, while birinapant and FasL combination therapy showed synergistic or additive effects in most cell lines tested [68,76]. Here, FASLG is linked to head and neck squamous cell carcinoma.